Compare LBRX & HLF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRX | HLF |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2025 | 2004 |
| Metric | LBRX | HLF |
|---|---|---|
| Price | $47.00 | $12.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $46.60 | $18.00 |
| AVG Volume (30 Days) | 285.4K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.22 | N/A |
| EPS | N/A | ★ 0.33 |
| Revenue | N/A | ★ $5,037,500,000.00 |
| Revenue This Year | N/A | $4.97 |
| Revenue Next Year | N/A | $3.80 |
| P/E Ratio | ★ N/A | $36.97 |
| Revenue Growth | N/A | ★ 0.89 |
| 52 Week Low | $13.40 | $7.56 |
| 52 Week High | $50.16 | $20.40 |
| Indicator | LBRX | HLF |
|---|---|---|
| Relative Strength Index (RSI) | 56.39 | 50.04 |
| Support Level | $21.90 | $11.43 |
| Resistance Level | $49.65 | $13.13 |
| Average True Range (ATR) | 2.02 | 0.55 |
| MACD | -0.53 | -0.03 |
| Stochastic Oscillator | 30.43 | 69.11 |
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
Herbalife Ltd is a health and wellness company. It provides health and wellness products in 95 markets through a direct-selling business model. Its product categories include Weight Management, Targeted Nutrition, Energy, Sports and Fitness, Outer Nutrition, and Literature, Promotional, and Other. Weight Management generates the majority of revenue, with products such as meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Products are manufactured at facilities in Changsha and Suzhou, China; Lake Forest, California; and Winston-Salem, North Carolina, as well as by third-party providers. Revenues reflect sales to Members across North America, Latin America, EMEA, Asia Pacific, and China.